Publications by authors named "Mulligan S"

Background: We previously published the protocol and statistical analysis plan for a randomized controlled trial of Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: the PROMIZING study in Trials ( https://doi.org/10.1186/s13063-023-07163-w ).

View Article and Find Full Text PDF

Quadrupedal movement training (QMT) is a unique form of bodyweight training shown to improve flexibility, FMS scores, and proprioception, however, little is known about its muscle activation characteristics. Therefore, the purpose of this study was to compare surface EMG (sEMG) activity of muscles of the trunk, upper, and lower extremity during QMT movements and common traditional bodyweight exercises (TRA). Twenty (males n = 9) participants (age: 27.

View Article and Find Full Text PDF

Background: Bowel dysfunction can significantly impair quality of life. Adequate fibre intake is associated with good bowel health but intakes have been reported to be low in Ireland.

Aim: This study aimed to gather data on fibre intake and bowel habits in a cohort of adults at a university campus in Dublin, Ireland.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic significantly disrupted clinical trials globally, leading to issues such as premature closures and compromised trial integrity, necessitating changes in research protocols.
  • The study aimed to assess challenges faced during interrupted critical care trials, identifying barriers and developing strategies for future trials based on input from principal investigators and project coordinators.
  • Results indicated that major challenges included the prioritization of COVID-19 studies and restrictions on hospital visitation, while participants offered various solutions and suggestions to enhance trial conduct moving forward.
View Article and Find Full Text PDF

Population-based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow-up data on rates of SPM.

View Article and Find Full Text PDF

Non-invasive prenatal screening provides a risk assessment for aneuploidies by utilizing cell-free DNA (cfDNA). It is recommended that cell-free DNA screening (cfDNA screening) be offered to all pregnant people regardless of a priori risk for aneuploidy. In the absence of an increased risk, alternative motives for electing cfDNA screening and different levels of informed decision making may arise.

View Article and Find Full Text PDF

Objective This study aims to provide insight into the attitudes and perspectives of undergraduate dental students from UK dental schools regarding environmental sustainability in dentistry (ESD) and the manner and extent in which ESD is included in the current undergraduate oral health care curricula.Methods This study is a multi-centre, nationally representive study involving a cross-sectional online survey of undergraduate Bachelor of Dental Surgery and dental hygiene and therapy students in UK-based dental schools. Data analysis was conducted through descriptive statistics and thematic analysis.

View Article and Find Full Text PDF
Article Synopsis
  • The phase 3 ASPEN trial compared the effectiveness of two BTK inhibitors, zanubrutinib and ibrutinib, in treating Waldenström macroglobulinemia, analyzing genetic mutations' impact on treatment response.
  • The study found that patients with mutations in CXCR4 and TP53 had poorer responses and survival rates but those treated with zanubrutinib generally showed better outcomes than those given ibrutinib.
  • Overall, the research indicated that zanubrutinib offers improved clinical outcomes for patients with specific mutations compared to ibrutinib, highlighting the importance of genetic testing in treatment decision-making.
View Article and Find Full Text PDF

Objectives: To undertake a comparative ecological impact (Total lifetime carbon footprint and single use plastics (SUP) waste generation) derived from the provision of professional oral healthcare (Dentists and hygienist) to five different patient categories up to the age of 50 years, representative of different levels of progressive dental disease and treatment experience.

Method: COe and SUP waste generated was calculated for five patient categories with common preventable diseases; that are representative of different levels of progressive dental disease and treatment experience. The assessment is based on the average restorative care levels for 50-year-olds in the UK.

View Article and Find Full Text PDF

Despite advances in treatment, a significant proportion of patients with chronic lymphocytic leukemia (CLL) will relapse with drug-resistant disease. The imipridones, ONC-201 and ONC-212, are effective against a range of different cancers, including acute myeloid leukemia (AML) and tumors of the brain, breast, and prostate. These drugs induce cell death through activation of the mitochondrial protease, caseinolytic protease (CIpP), and the unfolded protein response (UPR).

View Article and Find Full Text PDF

Despite widespread vaccination rates, we are living with high transmission rates of SARS-CoV-2. Although overall hospitalisation rates are falling, the risk of serious infection remains high for patients who are immunocompromised because of haematological malignancies. In light of the ongoing pandemic and the development of multiple agents for treatment, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 management in patients with haematological disorders.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with chronic lymphocytic leukemia (CLL) have a significantly heightened risk of developing other malignancies (OMs), with a study tracking nearly 20,000 CLL patients revealing 3,513 OMs diagnosed over 129,254 years of follow-up.
  • The study found that treatment with fludarabine and cyclophosphamide increased the likelihood of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), while non-melanoma skin cancer (NMSC) and prostate cancer were common solid tumors in treated patients.
  • Importantly, patients with CLL who developed OMs had lower overall survival rates, especially those diagnosed with AML and MDS, highlighting that C
View Article and Find Full Text PDF
Article Synopsis
  • In Australia, over 50% of patients with relapsed or refractory chronic lymphocytic leukaemia on ibrutinib also take proton pump inhibitors (PPIs).
  • High gastric pH caused by PPIs can lower the effectiveness of some Bruton tyrosine kinase inhibitors, including ibrutinib.
  • The study found no significant impact of PPI use on how long patients remain on ibrutinib treatment (P = 0.61), indicating that PPIs do not affect treatment persistence.
View Article and Find Full Text PDF
Article Synopsis
  • - Chronic lymphocytic leukaemia (CLL) is the most common blood cancer in Australia and New Zealand, with significant advancements in diagnosis and treatment in the past decade.
  • - New technologies like next-generation sequencing and flow cytometry help doctors predict outcomes and monitor treatment responses more effectively, while new therapies have improved care for patients, especially those with high-risk genetic issues.
  • - Given the unique healthcare landscape in Australasia, experts have created a consensus practice statement to provide standardized guidelines for CLL diagnosis and management, keeping in mind public health concerns like the COVID-19 pandemic.
View Article and Find Full Text PDF

This paper aims to highlight to the reader that the organisation of dentistry at a system level lags behind other healthcare professions in regulation, policy, education and research. It argues that seeing sustainability as being as important as safety in oral healthcare quality would begin to rectify this. For the practitioner, it also identifies existing guidance on practising sustainably and reinforces that it does not require radical change but evidence-based care.

View Article and Find Full Text PDF
Article Synopsis
  • The study looked at how many babies were born from eggs taken during in vitro fertilization (IVF) at a fertility clinic from 2014 to 2020.
  • They wanted to see the birth rate per egg collected, especially after all embryos were used, and guess how many babies could be born from frozen embryos.
  • They found that out of a lot of patients, only about 2.82% of the eggs led to a live birth, but this number changed depending on the age of the patients and if they used a special test called PGT-A.
View Article and Find Full Text PDF

We analysed COVID-19 infection outcomes of 129/241 chronic lymphocytic leukaemia (CLL) (53.9%) and 22/55 monoclonal B-lymphocytosis (MBL) (40.0%) patients following multiple vaccine doses aiming for maximum measured anti-spike antibody response.

View Article and Find Full Text PDF
Article Synopsis
  • The phase III ASPEN study showed that zanubrutinib is as effective as ibrutinib but has better safety for treating patients with Waldenström macroglobulinemia (WM).
  • In a long-term follow-up, zanubrutinib demonstrated higher rates of very good partial response and complete response compared to ibrutinib in both cohorts of WM patients.
  • Adverse events like diarrhea, muscle spasms, and hypertension were more common with ibrutinib, while zanubrutinib had a lower risk of treatment-related discontinuation.
View Article and Find Full Text PDF
Article Synopsis
  • Patients with chronic lymphocytic leukemia (CLL) on ibrutinib treatment often develop resistance due to mutations in the BTK and PLCG2 genes, with varying frequencies impacting patient outcomes.
  • A study of 98 CLL patients revealed that 65% of those who relapsed exhibited at least one mutation in BTK or PLCG2, while 12% of responding patients also had mutations, indicating a potential for progression.
  • The findings suggest that other genetic mutations may contribute to resistance, with BTK mutation profiles differing between relapsing patients, but no significant impact on TP53 mutations was observed, highlighting the complexity of treatment resistance.
View Article and Find Full Text PDF